Use of Apoptosis-specific eIF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
OwnerJohn E. Thompson, Charles A. Dinarelloinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for down regulating pro-inflammatory cytokines in a mammal by administering siRNA against eIF-5A1 to the mammal to treat/prevent sepsis and/or hemorrhagic shock.
Claims13
A method for decreasing expression of pro-inflammatory cytokines in vivo in a subject, comprising administering eIF5A1 siRNA to the subject, whereby the eIF5A1 siRNA decreases expression of pro-inflammatory cytokines in the subject.
A pharmaceutical composition for decreasing expression of pro-inflammatory cytokines, comprising eIF5A siRNA and a pharmaceutically acceptable carrier.
The composition of claim 11 wherein the sense strand of the siRNA comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29 and SEQ ID NO:32.
A method of preventing hemorrhagic shock in a subject comprising administering an eIF5A1 siRNA or eIFA1 antisense polynucleotide to decrease expression of IL-1β and/or TNF-α in the subject, thereby preventing hemorrhagic shock.
Dependencies are inferred from the claim text.